Clinical trial
Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Rengalin in the Treatment of Cough in Acute Viral Upper Respiratory Tract Infections Tract Infections in Children During the Epidemic Growth of Influenza and ARVI
NCT07171099 is registered in ClinicalTrials.gov with Materia Medica Holding as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Rengalin in the Treatment of Cough in Acute Viral Upper Respiratory Tract Infections Tract Infections in Children During the Epidemic Growth of Influenza and ARVI
- Lead sponsor
- Materia Medica Holding
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- October 3, 2025
- Completion date
- December 31, 2028
- Enrollment
- 264 (estimated)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.